Evidence map›Paper›PMID 41028777›Full record

ArticleScientific reports2025

Application of chemical similarity and bioisosteres to find allosteric inhibitors of type 2 lipid kinase γ.

Priyanka Andola, Jishu Pagag, Gatta K R S Naresh, Lalitha Guruprasad

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Priyanka AndolaSchool of Chemistry, University of Hyderabad, Hyderabad, 500046, India.
Jishu PagagSchool of Chemistry, University of Hyderabad, Hyderabad, 500046, India.
Gatta K R S NareshSchool of Chemistry, University of Hyderabad, Hyderabad, 500046, India.
Lalitha GuruprasadSchool of Chemistry, University of Hyderabad, Hyderabad, 500046, India. lalitha.guruprasad@uohyd.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphatidylinositol phosphate kinases (PIPKs) exist in three isoforms: I, II, and III. Some of these enzymes are promising drug targets for cancer, metabolic disorders, and neurodegenerative diseases. Type II PIPKs are notable for their dual roles, to perform phosphorylation reactions acting as lipid kinases and to carry out catalytic-independent functions. The dysregulation of Type II PIPKs is linked to several diseases, including psychiatric disorders, cancer, and infections. There is still a need to explore for strong inhibitors of these kinases. This study used a similarity search method to find analogs of the known PI5P4K2C inhibitor, DVF (5-methyl-2-(2-propan-2-ylphenyl)-N-(pyridin-2-ylmethyl)pyrrolo[3,2-d]pyrimidin-4-amine). It utilized open-access platforms like SwissSimilarity, SwissBioisosteres, and the STITCH database for the initial screening of molecules. Drug-likeness assessment of the selected molecules was followed by molecular docking and molecular dynamics simulations to evaluate their binding affinity and stability. Post-simulation analysis revealed four promising hit compounds, each containing a pyrrole-pyrimidine core, which exhibited superior binding free energies and interactions at the allosteric site compared to DVF. These findings highlight potential candidates for further development as PI5P4K2C inhibitors.

Indexed as

Enzyme InhibitorsPhosphotransferases (Alcohol Group Acceptor)Protein Kinase InhibitorsAllosteric RegulationHumansMolecular Docking SimulationMolecular Dynamics SimulationEnzyme InhibitorsPhosphotransferases (Alcohol Group Acceptor)Protein Kinase InhibitorsAllosteric siteMM-PBSAMolecular dockingMolecular dynamics simulationsType II phosphatidylinositol 5-phosphate 4-kinase

Identifiers

PMID41028777
PMCPMC12485083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.